Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

Summary

The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.

Timeline

Start

2014-01

Primary completion

2014-05

Completion

2014-05

Outcome

Mixed primary results

registry A: Placebo vs B: Donepezil 10 mg; p = 0.573; LS mean difference -0.31 (95% CI -1.4 to 0.8) NCT02051335 ↗

registry A: Placebo vs D: Roflumilast Dose A + Donepezil 10 mg; p = 0.042; LS mean difference 2.01 (95% CI 0.1 to 4.0) NCT02051335 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Donepezil	Small molecule	10 mg	Oral
Subject	Roflumilast	Small molecule	—	Oral
Background	Scopolamine	Unknown	0.5 mg	Subcutaneous

Indications